Skip to main content

Table 3 Measurement domains, survey methods and collection time-points

From: Evaluation of the “safe multidisciplinary app-assisted remote patient-self-testing (SMART) model” for warfarin home management during the COVID-19 pandemic: study protocol of a multi-center randomized controlled trial

Variable Component Measurement methods Baseline 3rd
9th M 12th M
Socio-demographic parameters Gender, age, telephone, address, education, occupation and annual income Face-to-face interview     
Clinical parameters Height, weight, warfarin indication, start date of warfarin, warfarin dosage, TTR calculated by INR tests in the preceding 12 months, history of thrombosis or major bleeding, concomitant diseases and medicine
Warfarin dosage, INR, bleeding or thrombosis, other clinical adverse events
Face-to-face interview     
Face-to-face interview, telephone or online interview  
Behaviour parameters Anticoagulant compliance, warfarin knowledge, Morisky Anticoagulant Compliance Questionnaire [14], Oral Anticoagulation Knowledge (OAK) Test [15]    
Treatment behavior, quality of life Self-made questionnaire,
EQ-5D-3L Form [16]
Anticoagulation satisfaction Duke Anticoagulation Satisfaction Scale [17]     
Economic parameters Direct costs (INR test fees, outpatient clinic visit fees, hospitalization or emergency room visit fees if occurs), Indirect costs (deducted income due to absence of working, traffic and accommodation fees) Face-to-face interview, telephone or online interview